Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.07.26.221861v1?rss=1 Authors: Sun, W., Leist, S. R., McCroskery, S., Liu, Y., Slamanig, S., Oliva, J., Amanat, F., Schaefer, A., Dinnon, K., Garcia-Sastre, A., Krammer, F., Baric, R. S., Palese, P. Abstract: Due to the lack of protective immunity of humans towards the newly emerged SARS-CoV-2, this virus has caused a massive pandemic across the world resulting in hundreds of thousands of deaths. Thus, a vaccine is urgently needed to contain the spread of the virus. Here, we describe Newcastle disease virus (NDV) vector vaccines expressing the spike protein of SARS-CoV-2 in its wild type or a pre-fusion membrane anchored format. All described NDV vector vaccines grow to high titers in embryonated chicken eggs. In a proof of principle mouse study, we report that the NDV vector vaccines elicit high levels of antibodies that are neutralizing when the vaccine is given intramuscularly. Importantly, these COVID-19 vaccine candidates protect mice from a mouse-adapted SARS-CoV-2 challenge with no detectable viral titer and viral antigen in the lungs. Copy rights belong to original authors. Visit the link for more info